Influenza infection can be severe in bone marrow transplant (BMT) recipients. Although yearly epidemics occur worldwide, and a higher risk of complication is expected in these patients, few studies have addressed the impact of the new neuraminidase inhibitors in the prognosis of influenza after BMT. Influenza A or B infections were found in 39 of the 66 patients (59%) showing a positive nasal wash by DFA. Influenza A was diagnosed in 18 patients and influenza B in 23 patients; two patients were infected by influenza A and B with 84-and 90-day intervals between episodes, respectively. Of the 41 episodes (61%) of influenza A or B, 25 infections occurred during the spring and summer months. Oseltamivir was introduced within 48 h of symptoms appearing. Only two patients (5.1%) developed influenza pneumonia, and no patient died of influenza. A total of 22 patients (56.4%) acquired influenza before day þ 180 when preventive vaccination strategies are precluded owing to poor immunogenicity of the vaccine during this period. Oseltamivir proved to be safe and appears to have played an important role in the outcome of influenza infection in this population. The therapeutic and/or prophylactic benefits of Oseltamivir in BMT recipients remain to be demonstrated in randomized, prospective trials.
Influenza infection can be severe in bone marrow transplant (BMT) recipients. Although yearly epidemics occur worldwide, and a higher risk of complication is expected in these patients, few studies have addressed the impact of the new neuraminidase inhibitors in the prognosis of influenza after BMT. Influenza A or B infections were found in 39 of the 66 patients (59%) showing a positive nasal wash by DFA. Influenza A was diagnosed in 18 patients and influenza B in 23 patients; two patients were infected by influenza A and B with 84-and 90-day intervals between episodes, respectively. Of the 41 episodes (61%) of influenza A or B, 25 infections occurred during the spring and summer months. Oseltamivir was introduced within 48 h of symptoms appearing. Only two patients (5.1%) developed influenza pneumonia, and no patient died of influenza. A total of 22 patients (56.4%) acquired influenza before day þ 180 when preventive vaccination strategies are precluded owing to poor immunogenicity of the vaccine during this period. Oseltamivir proved to be safe and appears to have played an important role in the outcome of influenza infection in this population. The therapeutic and/or prophylactic benefits of Oseltamivir in BMT recipients remain to be demonstrated in randomized, prospective trials. With regard to respiratory viruses (RV), preventive strategies provide the key to reducing the impact of such infections in BMT recipients. Among the known respiratory viruses, vaccination strategy and effective antiviral therapy are available only for influenza viruses. Although influenza continues to cause annual, worldwide epidemics, and a higher risk of complication in BMT recipients, [1] [2] [3] [4] surprisingly few studies have addressed the impact of influenza vaccination or of early, antiviral intervention with the new neuraminidase (NA) inhibitors, Zanamivir and Oseltamivir. [5] [6] [7] Oseltamivir is a potent and selective inhibitor of the NA glycoprotein, essential for replication of the influenza A and B viruses. This drug inhibits sialidase activity, and compared to Amantadine, provides clear advantages such as activity against both influenza A and B viruses, an improved safety profile, and a low potential for inducing resistance. 8 However, therapeutic benefit has been demonstrated only in controlled trials in which treatment was begun within 48 h of the onset of symptoms, emphasizing the essential role for rapid diagnosis.
In the present study, we report on the therapeutic strategies and clinical outcome in BMT recipients who acquired influenza A and/or B infection. All patients were warned of the risks of RV infection. During the RV season, outpatients with respiratory symptoms were required to return to the day-hospital for sample collection. Chest radiographs were performed concomitantly to evaluate the presence of pulmonary infiltrates. When clinically indicated, patients underwent bronchoalveolar lavage (BAL). A direct immunofluorescence assay (Imagen s DAKO, Cambridgeshire, UK) was performed according to the manufacturer's instructions, and the results were obtained within 24 h of sample collection. Outpatients diagnosed with influenza were notified by telephone and asked to return to the day-hospital to begin treatment.
Patients and methods

Patients and nasal wash samples
Case definition
Influenza upper respiratory tract illness was defined as the presence of upper respiratory tract symptoms, a clear chest radiograph, and the presence of influenza A or B viruses as detected by direct immunofluorescence assay (DFA) in NW samples. Influenza lower respiratory illness was defined as the presence of pneumonia with a recent radiographic infiltrate, in a patient with a positive NW or BAL fluid. Respiratory virus coinfection was defined as present when more than one RV was identified in nasal washes taken within a 6-day interval.
Antiviral policy
All patients with a proven upper or lower respiratory tract influenza infection as detected by DFA were treated with Oseltamivir (75 mg twice a day for 5 days) provided by the BMT program. Patients were asked to report side effects by telephone or directly to the pharmacist or nurses assisting in the BMT program. The appearance of Oseltamivir resistance was not specifically investigated in the present study.
Results
During the study period, 319 patients were followed up by the BMT Program of the University of Sa˜o Paulo Medical School. Of these, 179 (56.1%) developed respiratory symptoms during the study period, and 68 (38%) tested positively for respiratory viruses by immunofluorescence assay. Two patients who acquired respiratory virus infections immediately before conditioning were excluded from the present study since BMT was postponed. All patients received myeloablative marrow transplants. Patients' characteristics are shown in Table 1 .
Influenza A or B infections were seen in 39 of the 66 patients (59%) who had a positive NW. The underlying diseases were chronic myelogenous leukemia (CML) in 16 patients (41%), acute myelogenous leukemia (AML) in eight (20.5%), acute lymphoblastic leukemia (ALL) in four (10.2%), non-Hodgkin lymphoma in four (10.2%), and other diseases in seven patients (17.9%). The conditioning regimen consisted of Busulfan and Melphalan in 22 patients (56.4%), total body irradiation and Cyclophosphamide in six (15.4%), and Busulfan and Cyclophosphamide in three patients (7.7%), while eight patients (20.5%) received other conditioning regimens. Three of the 31 allogeneic BMT recipients (9.7%) with influenza were not taking immunosuppressive drugs. Of the 12 patients who acquired influenza before day þ 100, acute GVHDX II was present in four (33.3%). In the remaining 19 patients, chronic GVHD was seen in 11 patients (57.9%).
A total of 23 patients (58.9%) had received BMT within 6 months, and 12 had acquired influenza before engraftment (median 8 days after BMT). With regard to the severity of influenza and the duration of viral antigen detection, no difference was found between patients who acquired influenza before engraftment and those who were infected later. Among the remaining 16 patients with influenza after day þ 180, only two had received influenza vaccine owing to poor compliance with the vaccination program.
In 23 patients from whom two or more NW were taken within a 7-day interval, two (8.7%) showed influenza antigens, as detected by DFA, for more than 7 days. Both were allogeneic BMT recipients, had acquired influenza on days þ 4 and þ 329, respectively, and tested positive by DFA for at least 21 and 28 days, respectively. One patient was receiving Cyclosporine alone, while the other had extensive, chronic GVHD and was receiving Cyclosporine and Prednisone.
Influenza A was diagnosed in 18 patients and influenza B in 23 patients. Two patients acquired influenza A and B infections with 84-and 90-day intervals between episodes, respectively. Of the 18 patients (88.8%) infected with influenza A, 16 were allogeneic BMT recipients as were 16 of the 23 patients (69.5%) with influenza B. The seasonal distribution of influenza A and B viruses among BMT recipients has been published elsewhere 7 and is similar to that observed in the community, over the same period (unpublished data from the Adolfo Lutz Institute, State Health Department). Only five of the 41 episodes (12.2%) of influenza A or B infection occurred during the summer months.
Three patients with influenza A infection received Amantadine (100 mg b.i.d. for 5 days) since Oseltamivir was not available to the BMT unit when requested. One of these patients who had received Oseltamivir as treatment had a previous episode of influenza B infection. All other patients were given Oseltamivir and began treatment within the first 48 h of the appearance of respiratory symptoms. No major or moderate side effects were reported during Oseltamivir or Amantadine therapy. Two of the 39 patients (5.1%) with upper respiratory tract influenza infection developed interstitial pneumonia as seen in tomographic images, and showed a positive BAL for influenza viruses. One patient had influenza B/RSV coinfection, and the remaining patient developed influenza A pneumonia 4 months after an episode of upper RSV infection. No patient died of influenza pneumonia (Table 2) .
Discussion
In the present study, we found a high prevalence of influenza infection among symptomatic BMT recipients. Influenza B infection predominated over influenza A, which seems to occur every 2 or 3 years 10 and particularly in the study period.
Although the present study was not randomized or controlled to evaluate the effectiveness of Oseltamivir therapy in the prognosis of influenza infection among BMT recipients, the present data suggest that an early diagnosis followed by Oseltamivir therapy may have played an important role in preventing influenza complications in this setting.
Few patients developed a high fever, and interestingly, the chills and rigors, typical of influenza in immunocompetent hosts, were not seen in this series. Another BMT center has reported similar findings.
2 Historically, the rates of influenza pneumonia in BMT recipients vary from 9.5 to 75% in different studies. [1] [2] [3] [4] Only two patients (5.1%) developed pneumonia in the present series, and it is likely that in the remaining 37 patients, antiviral therapy may have played some role in preventing the progression of upper respiratory tract influenza infection. In healthy, nonimmunized adults with influenza, Oseltamivir therapy reduced the severity of illness by 38%, and the frequency of physician-diagnosed, secondary complications leading to antibiotic prescriptions was halved.
11
Yearly vaccination is the preferred strategy to control influenza infection in BMT recipients, and is recommended annually for patients after day þ 180. 12 The high incidence of influenza observed in the present series may be partially explained by the low compliance with current vaccine recommendations.
However, 23 patients with influenza in this study (58.9%) acquired the infection before day þ 180, when a preventive vaccination strategy is limited. Although the influenza vaccine has been administered as early as 4 months after stem cell transplantation, 13 the immunogenicity of the vaccine within the first 6 months of transplantation is poor. This fact raises certain concerns and provides the following perspectives:
These patients may represent a source of influenza infection to other high-risk patients and HCWs. Since the influenza vaccine is safe, in an epidemic situation some patients may benefit from early vaccination. Further, the studies published on the influenza vaccine only provide immunological end points and, even in those patients considered poor responders to vaccination, the severity of influenza as well as transmission among other patients and HCWs may be decreased.
Whenever an immunization strategy fails, rapid diagnosis and early treatment with Oseltamivir may help to control influenza complications and restrict virus spread in hospitals and outpatient settings by shortening the period of virus shedding, as seen in experimental, human influenza.
14 In the present study, the influenza antigen was detected for 7 days or more in less than 9% of the BMT recipients infected by influenza and receiving Oseltamivir.
Although not specifically investigated here, Oseltamivir resistance is unlikely to be the cause of this prolonged antigen detection since therapy lasted only for 5 days. Many studies have been conducted worldwide to evaluate the emergence of influenza viruses resistant to Oseltamivir. However, no data are currently available concerning the impact of circulation of Oseltamivir-resistant influenza viruses among high-risk patients after prolonged Oseltamivir prophylaxis.
Finally, due to the high attack rates of influenza infection, BMT recipients before day þ 180 should be considered as a target population for prospective controlled trials that evaluate the effectiveness of prophylaxis with the new neuraminidase inhibitors, and to address its role in the appearance of Oseltamivir or Zanamivir resistance.
We conclude that influenza infection is highly prevalent among BMT recipients in the Southeastern region of Brazil. Oseltamivir therapy proved to be safe in this population, and prospective controlled trials are necessary to evaluate its role as an alternative strategy for patients within the first 6 months of BMT or in the case of influenza vaccine failures. 
